Predicting response to liver cancer treatment
Part of Cancer, Digestive system clinical trials.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC).
- You are currently taking or have taken atezolizumab (Tecentriq) combined with bevacizumab (Avastin).
- You are 18 years or older.
- You have a recent CT scan (with contrast) taken within the month before starting treatment.
- You do not have any other type of cancer right now.
- You are generally able to get out of bed and take care of yourself (your performance status is 2 or lower).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at people with advanced liver cancer (HCC) that cannot be removed by surgery. Researchers want to see if certain markers in your blood or tumor can help predict how well you respond to a combination of chemotherapy delivered directly to the liver and immunotherapy. If you join, you will receive the planned treatment and provide additional blood and tissue samples for analysis.
This study looks at whether certain blood markers can predict how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer. It aims to find out if these markers can help guide treatment decisions.
This study tries to predict how well your cancer responds early after starting a treatment called atezolizumab plus bevacizumab. If you qualify, your information may help doctors choose better treatments sooner for people with advanced liver cancer.
This study looks at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer in real life, outside of a clinical trial. It will help doctors understand the treatment's benefits and risks based on patient records.
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
This trial combines three medications—an immunotherapy (atezolizumab), a drug that blocks blood vessel growth (bevacizumab), and one that reduces inflammation (tocilizumab)—to see if they work together against advanced liver cancer. The goal is to slow cancer growth and possibly shrink the tumor.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.